Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.32 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.32 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.32 |
| ▸ | GLB1 | P16278 | 1/20 | 0.31 |
| ▸ | GBA1 | P04062 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24571398 | 1.00 | SMN1; SMN2 (0.42) | SMN1; SMN2GNAI3GNAO1GNAI1GLB1 | |
| SCHEMBL27424183 | 1.00 | SMN1; SMN2 (0.42) | SMN1; SMN2GNAI3GNAO1GNAI1GLB1 | |
| SCHEMBL18033870 | 0.83 | SMN1; SMN2 (0.42) | SMN1; SMN2GNAI3GNAO1GNAI1GLB1 | |
| SCHEMBL23491191 | 0.83 | SMN1; SMN2 (0.42) | SMN1; SMN2GNAI3GNAO1GNAI1GLB1 | |
| SCHEMBL14120089 | 0.80 | SMN1; SMN2 (0.42) | SMN1; SMN2GLB1GBA1HSD11B1 | |
| SCHEMBL23475172 | 0.80 | SMN1; SMN2 (0.42) | SMN1; SMN2GLB1GBA1HSD11B1 | |
| SCHEMBL13037926 | 0.80 | SMN1; SMN2 (0.42) | SMN1; SMN2GLB1GBA1HSD11B1 | |
| SCHEMBL12525024 | 0.80 | — | — | |
| SCHEMBL17553944 | 0.80 | — | — | |
| SCHEMBL12074182 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240279237-A1 | FUSED BICYCLIC HETEROARYL COMPOUNDS USEFUL AS NLRP3 INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2024-08-22 | — | — | US | disclosed |
| CN-118119626-A | Fused bicyclic heteroaryl compounds useful as NLRP3 inhibitors | 豪夫迈·罗氏有限公司 | 2024-05-31 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240279237-A1 | FUSED BICYCLIC HETEROARYL COMPOUNDS USEFUL AS NLRP3 INHIBITORS | NLRP3, NOD1, NLRP1 | SMN1; SMN2 4483/4885GNAI3 529/4885GNAO1 846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.